Drug intelligence / Profile preview

MH-001

Development stage: Phase 1
Lead developer: Vespina Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

MH-001 is an orally administered small molecule drug developed by Vespina Lifesciences. As of June 2025, it is a new molecular entity in early clinical development, with its mechanism of action currently undefined and not publicly disclosed. The drug is being evaluated in first-in-human Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. No specific therapeutic indication has been announced or published for MH-001 at this time[1][4][5][7][9].

Other names: MH 001MH001MH-001

Beyond the preview

Go deeper on MH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MH-001.

Explore the full profile